The approval is supported by data from a phase 3 study that assessed the efficacy and safety of Botox in patients aged 5 to 17 years with urinary incontinence due to NDO and using clean intermittent ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback